Draft Eposter NRSG 353

ALI = How does acute kidney disease progress to chronic? Discuss renal ischemia, nephrotoxins, and various modifiable factors such as unmanaged diabetes, preeclampsia, obesity, cardiovascular disease, hypertension and kidney trauma.
So, again, you basically need to say how acute kidney disease becomes chronic. Most of the evidence I have found suggests that is because of uncontrolled BP, nephrotoxic medications, and renal ischaemia. Don't include how you get acute or chronic kidney disease (eg. diet, age) - its just about how it progresses from acute to chronic.

Definition
Different Studies in 2008 to 2010 revealed that patients who survive an incident of AKI have at high risk for development of chronic renal disease. (Chawla et al., 2011)
Process of progression
Because the mechanisms for AKI to CKD progression are currently unknown
However some studies have been attended to evaluate the progression such as
Chawla et al., 2014 explained that damage of endothelial tissues, as part of tubulo-interstitial damge, and vascular insufficiency may lead to severe harmful rounds of tissue ischemia and hypoxia, sequentially involving renal cellular function. The combination of vascular inadequacy, glomerular hypertension, and interstitial fibrosis is a destructive set of self-reinforcing processes that extends injury, inhibits restoration, and lead to progressive tissue injury.
Refrence :
Chawla, L., Eggers, P., Star, R. and Kimmel, P. (2014). Acute Kidney Injury and Chronic Kidney Disease as Interconnected Syndromes. New England Journal of Medicine, 371(1), pp.58-66.
A patient who survived of AKI is recognized, what
What actions can be applied in order to minimize the risk progression to chronic condition?
Progression could be prevented by following measures
1. Regular monitoring of serial creatinine for evaluation to detect reversible causes of renal ischemia,
2. (2) rigorous control

of blood pressure within accepted guidelines, and
(3) Avoidance of medications that have significant nephrotoxic properties (for example, amphotericin, NSAIDs). More importantly, we believe that risk assessment tools such as the ones we propose can be used to identify patients for clinical trials. We envision a study wherein AKI survivors at risk for CKD
(Chawla et al., 2011)